KRAS and neoplasm: KRAS G12C was widely detected across the primary organ (9% for non–small-cell lung cancer, 3.9% for appendiceal cancer, 3.2% for colorectal cancer, 1.6% for tumor of unknown origin, 1.4% for small bowel cancer, and 1.3% for pancreatic cancer) [20].